Episode Details

Listeners: Watch the video if you can as our guest uses excellent visuals that are more than helpful.

Meeting assets for Space Show with Mari Anne Snow of Eascra, a Nanomedicine company are ready!

The following assets for the meeting - Space Show with Mari Anne Snow of Eascra, a Nanomedicine company are now available.

Our program began with guest Mari Anne Snow, CEO of EASCRA Biotech, focusing ion on the Eascra Biotech's innovative work in nanomedicine, including their space missions and development of Janus-based nanoparticles for medical applications. The discussion concluded with detailed exploration of the company's space-based manufacturing processes, potential profitability, and future plans for clinical trials and product development. Joining us in the Zoom meeting were Dr. A.J. Kothari, John Jossy, and Dr. Phil Swan. All of us spoke feely during the program.

David and Mari discussed the potential of regenerative medicine and its impact on orthopedic surgeries, particularly knee and hip replacements. Mari emphasized that their target customers are not orthopedic surgeons but rather payers and patients, as insurance often covers traditional replacements more readily than alternative treatments. They explored the market opportunities in conditions like osteoarthritis and neuromuscular injuries, as well as kidney diseases, with the goal of offering cost-effective and innovative treatments. David expressed interest in these topics and mentioned his experience with space medicine, noting the lack of awareness among doctors about emerging space medical technologies.

Mari, the Co-founder and CEO of Esker Biotech, discussed her company's innovative work in nanomedicine, focusing on precision therapy delivery solutions for various medical applications. She highlighted their progress, including completing five space missions in 24 months, as evidence of advancements in the commercial space economy. Mari explained that while Eascra is still in early stages and preclinical, they are gathering data to approach the FDA for regulatory approval of space-made products, with the goal of ensuring their space-produced items are equivalent to those made on Earth. The discussion also touched on the company's background, Mari’s experience, and the technical aspects of their work, including the challenges and opportunities in the space and medical fields.

Mari discussed her company’s journey from an academic spin-off of the University of Connecticut to becoming a space medicine company. She explained how the company initially focused on producing nanoparticles on Earth but transitioned to space-based manufacturing after receiving funding and opportunities from NASA's In Space Manufacturing Program. Mari detailed their successful space missions, including working with astronauts like Sunita Williams and Johnny Kim, and described their plans to automate future experiments for increased efficiency.

Mari explained her company's development of Janus-based nanoparticles for medical applications, including mRNA delivery for osteoarthritis treatment and a cell-free scaffold for cartilage regeneration. She described the nanoparticles' unique structure and delivery mechanism, which allows for better cell penetration and bioactivity compared to existing options. Mari also highlighted the advantages of producing these products in space, where microgravity leads to a more uniform and structurally sound scaffold, resulting in improved tissue regeneration and faster healing rates. Note that I did briefly stop her to explain “Janus-based nanoparticles,” a definition and explanation that was definitely helpful.

Mari explained their work on developing medical products, both on Earth and in space, and discussed their progress in gaining FDA approval for their space-created medical product. She mentioned that they have early-stage agreement with the FDA for establishing equivalency between Earth